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SHORT COMMUNICATION
Photodynamic therapy (PDT) is a highly effective 
treatment for superficial skin cancers and skin cancer 
precursors (1, 2). In PDT, the administration of a photo-
sensitizing drug, followed by its activation by a specific 
wavelength of light matching the absorbance of the 
sensitizer, leads to a phototoxic reaction destroying the 
tumour cells (3). Adverse effects include pain during the 
illumination, and erythema and crusting after treatment. 
Recently, several attempts have been made to improve 
the tolerability of PDT (4–6). Several topical porphyrin-
based photosensitizer precursors are available for PDT. 
Currently, amino-5-laevulinate (5-ALA) and its methyl 
ester (MAL) are widely used. Novel photosensitizer for-
mulations include 5-ALA nanoemulsion (BF-200 ALA) 
and a long-chain lipophilic 5-aminolaevulinate hexyl-
ester (HAL). These novel formulations can be used at 
low concentrations, which may increase the tolerability 
and reduce the costs of the treatment (7, 8). This non-
sponsored double-blinded pilot study tested the safety 
of PDT with BF-200 ALA and HAL at 2 different con-
centrations compared with MAL on healthy human skin.
MATERIALS AND METHODS
The study was approved by the local ethics committee. We 
included 7 healthy volunteers, aged between 26 and 34 years, 
with skin phototypes I–II, to receive PDT on the sun-protected 
sides of their forearms with 4 different photosensitizer precur-
sors: (i) MAL 16% (Metvix®, Galderma, Paris, France), (ii) 
BF-200 ALA (10% 5-ALA, Ameluz®, Biofrontera, Leverkusen, 
Germany), (iii) HAL 2%, and (iv) HAL 0.2%. The HAL creams 
were prepared from commercially available HAL powder (Hex-
vix®, Photocure, Oslo, Norway) by mixing it into a standard 
cream base (Unguentum M®, Allmirall, Madrid, Spain). The 
treatment sites were randomized using a web-based validated 
Research randomizer© and kept blinded from the subjects. Areas 
2 ×1082 cm at distances of 5 cm from each other were marked 
on the skin and gently curettaged. The photosensitizers were 
weighed to achieve a 0.5 mm layer on the skin (0.5 mm-layer 
thickness was determined using the formula: treatment area 
size (mm2)* 0.5 (mg/mm2)) and kept occluded under a light-
impermeable cover for 3 h. Afterwards the drugs were wiped off 
and areas were irradiated using red light-emitting diode (LED) 
light (Aktilite CL128, Garderma, Paris, France) to achieve a 
light dose of 37 J/cm2. Pain was recorded before, during and 
after the illumination using a visual analogue scale (VAS). 
Fluorescence images were taken before and immediately after 
the illumination using Wood’s light (Philips Burton®, Somer-
set, USA) and a digital camera (Canon Ixus 10 megapixels). 
Fluorescence intensity and photobleaching were calculated 
from the images using the MatLab© (Mathworks, Natick, MA, 
USA). The fluorescence index in arbitrary units (AU) was 
calculated by measuring the mean fluorescence of the treated 
area and dividing it by the fluorescence of untreated skin of 
the same patient. The severity of the reactions at 1 and 2 days 
was evaluated from photographs by a blinded observer (NNP) 
who was unaware of the randomization. In addition, ery thema 
was measured using a spectrometer (DermaSpectrometer®, 
Cortex Technology, Hadsund, Denmark) (9). Friedman’s test 
and Pearson’s correlation were used for statistical analyses.
RESULTS
Mean maximal pain during the illumination was signifi-
cantly lower for HAL 0.2% and HAL 2% compared with 
BF-200 ALA and MAL (p = 0.043). No significant dif-
ference was found in pain due to BF-200 ALA and MAL. 
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Fig. 1. (a) Mean maximal pain values during the illumination. 
Hexyl-ester (HAL) 0.2% and HAL 2% caused significantly less 
pain compared with amino-5-laevulinate (5-ALA) nanoemulsion 
(BF-200 ALA) and the methyl ester (MAL) of 5-ALA (p = 0.043), 
while no difference was found in the pain between BF-200 ALA 
and MAL. (b) Erythema% compared with the baseline. Directly 
after illumination the erythema values differed between all 
4 photosensitizers, p = 0.0041. During 2 post-treatment days 
HAL0.2% caused significantly less erythema compared with 
BF-200 ALA (p = 0.003 at the first and p = 0.001 at the second 
post-treatment day) and MAL (p = 0.043 at the first and p = 0.023 
on the second post-treatment day). No significant difference was 
found between MAL and BF-200 ALA or HAL 2%.
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The mean ± SD maximal pain scores (VAS 1–10) were 
4.2 ± 2.4 for BF-200 ALA, 3.8 ± 2.8 for MAL, 2.3 ± 2.2 
for 2% HAL and 1.6 ± 2.0 for 0.2% HAL (Fig. 1a).
The erythema values are shown in Fig. 1b. A significant 
difference was found in the erythema between HAL0.2% 
and BF-200 ALA (p = 0.003 on the first and p = 0.001 on 
the second post-treatment day), and between HAL0.2% 
and MAL (p = 0.043 on the first and p = 0.023 on the 
second post-treatment day). No significant difference 
was found between MAL and BF-200 ALA or HAL 2%.
The treatment reactions of the investigated com-
pounds are summarized in Table I. The reactions were 
similar on the second post-treatment day (Fig. S11). 
Reduction in the initial protoporphyrin fluorescence 
induced by the photosensitizers, i.e. photo-bleaching, 
can predict the treatment efficacy (10). After 3 h oc-
clusion the fluorescence was equal in the BF-200 ALA, 
MAL and HAL2% groups (ns), but lower in the HAL 
0.2% group (p = 0.043). Photobleaching was equal with 
BF-200 ALA, MAL and HAL2%, while significantly lo-
wer photobleaching was seen with HAL0.2% (p = 0.003 
and p = 0.023 compared with BF-200 ALA and MAL).
There was a strong positive correlation between 
photo-bleaching and the clinically assessed reaction 
severity2, and a weaker positive correlation between 
photobleaching and erythema measured with the spec-
trometer3. There was no correlation between mean 
maximal pain and photo-bleaching, erythema or total 
protoporphyrin IX (PpIX) fluorescence.
DISCUSSION
These results show that low-concentration HAL was 
better tolerated than BF-200 ALA or MAL with regards 
to pain and erythema. Interestingly, while better tolera-
ted, HAL2% produced similar fluorescence and photo-
bleaching to that of MAL and BF-200 ALA. The fact 
that all photosensitizers induced pain and erythema on 
non-photo-damaged healthy skin indicates that the effect 
of PDT is not completely specific to cancerous tissues. 
A limitation of our trial was the small sample size and 
the lack of an accurate fluorescence imaging system. As 
our study was limited to healthy human skin, further 
research is needed into the safety and efficacy of these 
novel photosensitizers in cancerous skin.
Previously PDT with MAL20% was less painful 
and caused less erythema compared with ALA20% 
on healthy sun-exposed human skin (11). We showed 
that BF-200 ALA was as well tolerated as MAL. This 
may be due to the lower concentration of 5-ALA in 
this nano-formulation. In UV-exposed mice, HAL2% 
induced similar epidermal fluorescence to that of MAL 
20% (12). Our finding of strong fluorescence and photo-
bleaching with only 2% HAL supports these findings 
and further indicates the better tolerability of HAL. 
These pilot results show better tolerability of low-
concentration HAL compared with BF-200 ALA and 
MAL on healthy human skin. However, further research 
is required to determine whether the treatment might 
be sufficiently effective without erythema and pain. 
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